Pembrolizumab and Pralatrexate in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphomas

Recruiting

This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment. Pralatrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and pralatrexate may work better in treating participants with peripheral T-cell lymphomas.

Study Type:    Interventional

Study Design:    

Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:    A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas                  

Conditions:  

Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides
Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Refractory Mycosis Fungoides
Skin Lymphoma
 

Intervention:  Biological: Pembrolizumab

                       Drug:  Pralatrexate     

Phase:  Phase 1/2

External Link:  https://clinicaltrials.gov/ct2/show/NCT03598998